3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials (2024)
- Authors:
- USP affiliated authors: SOUZA, ROBSON FRANCISCO DE - ICB ; CARVALHO, CRISTIANE RODRIGUES GUZZO - ICB ; AMORIM, VITOR MARTINS DE FREITAS - ICB ; FERRARI, ANIELLE SALVIANO DE ALMEIDA - ICB ; MERIGHI, DAVI GABRIEL SALUSTIANO - ICB ; SOUZA, ANACLETO SILVA DE - ICB
- Unidade: ICB
- DOI: 10.3390/v16060844
- Subjects: MICROBIOLOGIA; CATÁLISE; ANTIVIRAIS; COVID-19; CORONAVIRUS; INIBIDORES DE ENZIMAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Viruses ISSN:1999-4915
- ISSN: 1999-4915
- Volume/Número/Paginação/Ano: v. 16, n. 6, art. 844, 22 p., 2024
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
AMORIM, Vitor Martins de Freitas et al. 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials. Viruses ISSN:1999-4915, v. 16, n. 6, p. 22 , 2024Tradução . . Disponível em: https://doi.org/10.3390/v16060844. Acesso em: 29 dez. 2025. -
APA
Amorim, V. M. de F., Soares, E. P., Ferrari, A. S. de A., Merighi, D. G. S., Souza, A. S. de, Souza, R. F. de, & Guzzo, C. R. (2024). 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials. Viruses ISSN:1999-4915, 16( 6), 22 . doi:10.3390/v16060844 -
NLM
Amorim VM de F, Soares EP, Ferrari AS de A, Merighi DGS, Souza AS de, Souza RF de, Guzzo CR. 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials [Internet]. Viruses ISSN:1999-4915. 2024 ; 16( 6): 22 .[citado 2025 dez. 29 ] Available from: https://doi.org/10.3390/v16060844 -
Vancouver
Amorim VM de F, Soares EP, Ferrari AS de A, Merighi DGS, Souza AS de, Souza RF de, Guzzo CR. 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials [Internet]. Viruses ISSN:1999-4915. 2024 ; 16( 6): 22 .[citado 2025 dez. 29 ] Available from: https://doi.org/10.3390/v16060844 - Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility
- Molecular dynamics simulations suggest SARS-CoV-2 3CLpro mutations in Beta and Omicron variants do not alter binding affinities for cleavage sites of non-structural proteins
- Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors
- Molecular dynamics analysis of fast-spreading severe acute respiratory syndrome coronavirus 2 variants and their effects on the interaction with human angiotensin-converting enzyme 2
- Antagonistic trends between binding affinity and drug-Likeness in SARS-CoV-2 Mpro inhibitors revealed by machine learning
- Latin America’s dengue outbreak poses a global health threat
- Severe acute respiratory syndrome Coronavirus 2 variants of concern: a perspective for emerging more transmissible and vaccine-resistant strains
- Divalent cations (Ca2+, Mg2+, Mn2+, Fe2+, Ni2+, and Zn2+) enhance growth of Xanthomonas citri and X. campestris by reducing generation time
- Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1)
- Biochemical and functional characterization of diguanylate cyclase LIC_11128 from Leptospira interrogans serovar copenhageni fiocruz strain L1-130
Informações sobre o DOI: 10.3390/v16060844 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
